List view / Grid view
Biologics are the fastest growing class of therapeutics in the biopharmaceutical industry. A key driver for this growth is success with anti-cancer immunotherapeutics such as checkpoint modulation, adoptive cell therapy and bispecific T-cell engagers. While these approaches use different tactics to attack tumours, they often employ monoclonal antibodies to target…
In this In-Depth Focus: hunting mysterious ‘Dark Matter Genome’ towards rewriting the rules of human genetic diseases, and enabling biomarker discovery at single-cell resolution
This webinar, held on 28 June 2018, illustrated the optimisation of hits derived from a target-agnostic phenotypic screen, using a strategy based on combining bioactivity profiling and reference compound characterisation. Keynote speaker Arsenio Nueda, Head of Molecular Biology at Almirall, responded as follows to questions posed during the webinar.
Flow cytometry has played a key role in drug development, largely due to its ability to measure up to twenty parameters on single cells or particles suspended in a fluid stream. Typically, cells are labelled with fluorescent markers and passed through a series of lasers, after which the resultant fluorescent…
This Assays In-Depth Focus looks at applications of high content screening in autophagy, and complex biology for the precision medicine era.
Stem cell-based technologies lay the basis for pioneering approaches in drug screening, toxicology testing, and regenerative medicine. The constant supply of high cell numbers in consistent quality needs scalable culture systems and standardised process conditions.
Cell therapies offer revolutionary new approaches for treating humandisease. Most of these treatments use GMP cytokines and growthfactors for the differentiation, expansion, and maintenance of cells.It is critical that GMP protein suppliers offer the optimal combinationof consistency, safety, and stable supply chain.
In this In-Depth Focus, Stefan R. Schmidt discusses the current status and future perspectives of monoclonal antibodies and Tony Edge explains why the determination of aggregate is critical in the formation of monoclonal antibodies.
Growing evidence reveals that using single immunotherapies to treat oncological disorders may lead to cancer-killing T-cell overdrive,initiating life-threatening autoimmune reactions including cytokinestorm; also known as hypercytokinemia or Cytokine Release Syndrome(CRS). Recently, checkpoint blockade using anti-programmed cell death1 (anti-PD-1) inhibitors became a prevalent approach for stimulatinganti-tumour immune system.
Workflows are generated around the analysis of large protein-derived therapeutics. The use of different analytical techniques is necessary to support drug development and testing, and thus increase generation of these new therapies. One of the areas that is most critical to this process is the determination of aggregates.
Since the first description of how to generate monoclonal antibodies was published in the 1970s, this field of research has grown tremendously. Currently, more than 70 full-length antibodies or fragments are approved by the major regulatory agencies globally. Looking back, a lot has changed since this historic discovery.
Assessing targets that are unable – or rather, extremely difficult – to reach pharmacologically, has prevented researchers from achieving desired clinical successes, most notably in the realm of cancer research. However, many advances are being made to shedlight on these difficult yet desirable target areas.
Live-cell analysis is now a well-established method that is part of the everyday cell biologist’s armoury for understanding cell biology. For over a decade, the functionality, throughput, and ease of use offered by real-time live-cell analysis has provided a platform for accurate and reproducible cell biology analysis in multiple biomedical…
Effective drug discovery and development relies largely on the availability of predictive pre-clinical model systems; the absence of which has contributed to late-stage drug failures and high expenditures. New industry acceptance of human induced pluripotent stem cell (hiPSC)-derived cardiomyocyte assay systems for regulatory safety pharmacology is now resulting in broad…
Drug discovery is a lengthy process that proceeds through several stages. High-throughput screening (HTS) utilising whole-cell-based screening assays plays a fundamental role as a starting point for identifying novel compounds in the drug discovery process.
